CClinicalTrials.gg
Not yet recruitingNCT07864090Updated Oct 7, 2026

Upper Extremity Orthoses Combined With Occupational Therapy in Subacute Stroke

An interventional study of Standardized Occupational Therapy and Dynamic Hand Orthosis in Stroke (Subacute), sponsored by University of Western Macedonia. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Western Macedonia · Not applicable, Interventional, and Treatment

Updated Oct 7, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial will investigate whether static or dynamic hand orthoses used as adjuncts to occupational therapy improve upper extremity recovery in adults with subacute stroke. Participants will be randomly assigned to one of three parallel groups: conventional occupational therapy alone, occupational therapy combined with a dynamic hand orthosis, or occupational therapy combined with a static hand orthosis. All groups will receive a standardized occupational therapy program for 4 weeks. Participants in the two orthosis groups will additionally use the assigned orthosis for 120 minutes per day, 5 days per week, following the occupational therapy session. Clinical outcomes will be assessed at baseline, at the end of the 4-week intervention, and at 8 weeks from the start of the intervention. The primary outcome will be upper extremity motor function assessed with the Fugl-Meyer Assessment of the Upper Extremity (FMA-UE).

Read the detailed description

The study is a prospective, randomized, controlled, assessor-blinded, three-arm parallel-group clinical trial involving adults with subacute stroke undergoing inpatient rehabilitation. Its objective is to evaluate the effects of static and dynamic hand orthoses used as adjuncts to a standardized occupational therapy program for upper extremity rehabilitation.

Following baseline assessment, eligible participants will be randomly allocated to one of three groups: occupational therapy alone, occupational therapy combined with a dynamic hand orthosis, or occupational therapy combined with a static hand orthosis. All participants will receive a standardized occupational therapy program consisting of 45-minute sessions, 5 days per week for 4 weeks, for a planned total of 20 sessions.

The occupational therapy program will follow a common therapeutic framework across all groups and will be individualized according to each participant's motor and functional status. Treatment may include upper extremity mobilization, motor control training, hand function activities, muscle activation and strengthening, task-oriented functional activities, activities of daily living, sensory retraining when clinically indicated, and motor learning strategies.

Participants allocated to either orthosis group will additionally use the assigned hand orthosis for 120 minutes per day, 5 days per week for 4 weeks, following the occupational therapy session. Adherence, tolerance, and safety related to orthosis use will be monitored throughout the intervention period.

Outcome assessments will be conducted by independent assessors blinded to group allocation at baseline, at Week 4, immediately following completion of the intervention, and at Week 8 from the start of the intervention. The primary outcome will be upper extremity motor function assessed using the Fugl-Meyer Assessment of the Upper Extremity (FMA-UE). Secondary outcomes will include muscle tone, muscle strength, grip strength, gross manual dexterity, functional independence in activities of daily living, and pain.

02

Conditions studied

  • Stroke (Subacute)

Browse trials for

Keywords

  • Occupational Therapy
  • Upper Extremity Rehabilitation
  • Hand Orthoses
  • Subacute Stroke
  • Motor Recovery
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 102 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of Western Macedonia is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥18 years.
  • First-ever stroke confirmed by CT or MRI (ischemic or hemorrhagic).
  • Time since stroke: from Day 8 to 6 months (subacute phase of recovery).
  • Presence of motor impairment in the affected upper extremity.
  • Modified Ashworth Scale (MAS) score of 0-3 in the affected upper extremity.
  • Montreal Cognitive Assessment (MoCA) score ≥11.
  • Ability to understand and follow simple one- to two-step commands.
  • Ability to remain seated for approximately 45 minutes.
  • Clinically stable condition.
  • Provision of written informed consent

Exclusion criteria

Exclusion Criteria:

  • Previous stroke.
  • Other significant neurological disorder affecting upper extremity function (e.g., Parkinson disease, multiple sclerosis, peripheral neuropathy).
  • Severe upper extremity spasticity (MAS = 4).
  • Severe cognitive impairment (MoCA \<11).
  • Absence of upper extremity motor impairment.
  • Severe orthopedic condition or anatomical deformity of the affected upper extremity that substantially limits passive movement or safe orthosis application.
  • Unstable clinical condition.
  • Severe pain in the affected upper extremity that limits movement and/or safe orthosis application (VAS ≥75/100 or pain that restricts passive movement/orthosis fitting).
  • Inability to remain seated for approximately 45 minutes.
  • Severe or uncontrolled psychiatric disorder affecting safety or cooperation.
  • Skin lesions, ulcers, or other conditions of the affected upper extremity that preclude safe orthosis use.
  • Botulinum toxin type A injection in the affected upper extremity within the previous 4 months or a planned injection during the study period.
  • Inability to cooperate with or adhere to the study protocol.
  • Participation in another clinical trial or recent intervention that may influence study outcomes.
  • Inability to provide valid informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    Occupational Therapy Alone

    Participants will receive a standardized occupational therapy program consisting of 45-minute sessions, 5 days per week for 4 weeks, for a planned total of 20 sessions. No upper extremity orthosis will be used as part of the study intervention.

    Behavioral: Standardized Occupational Therapy

  • Experimental
    Occupational Therapy Plus Dynamic Hand Orthosis

    Participants will receive the same standardized occupational therapy program as the control group and will additionally use a dynamic hand orthosis for 120 minutes per day, 5 days per week for 4 weeks, following the occupational therapy session.

    Behavioral: Standardized Occupational Therapy · Device: Dynamic Hand Orthosis

  • Experimental
    Occupational Therapy Plus Static Hand Orthosis

    Participants will receive the same standardized occupational therapy program as the control group and will additionally use a static hand orthosis for 120 minutes per day, 5 days per week for 4 weeks, following the occupational therapy session.

    Behavioral: Standardized Occupational Therapy · Device: Static Resting Hand Orthosis

Interventions

  • BehavioralStandardized Occupational Therapy

    A standardized, individualized occupational therapy program focused on upper extremity rehabilitation. Treatment may include mobilization, motor control training, hand function activities, muscle activation and strengthening, task-oriented functional activities, activities of daily living, sensory retraining when clinically indicated, and motor learning strategies. Sessions will last 45 minutes and will be delivered 5 days per week for 4 weeks, for a planned total of 20 sessions.

  • DeviceDynamic Hand Orthosis

    A dynamic hand orthosis used as an adjunct to the standardized occupational therapy program. The orthosis will be worn for 120 minutes per day, 5 days per week for 4 weeks, following completion of the occupational therapy session. Adherence, tolerance, and safety related to orthosis use will be monitored throughout the intervention period.

    Also known as: Aurafix ORT-07A Thermoplastic Dynamic Splint

  • DeviceStatic Resting Hand Orthosis

    A commercially available static resting hand orthosis (VITA Orthopaedics Resting Hand Orthosis 03-2-005) used as an adjunct to the standardized occupational therapy program. The orthosis will be worn for 120 minutes per day, 5 days per week for 4 weeks, following completion of the occupational therapy session. Adherence, tolerance, and safety related to orthosis use will be monitored throughout the intervention period.

    Also known as: VITA Orthopaedics Resting Hand Orthosis 03-2-005

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment of the Upper Extremity (FMA-UE)

    Upper extremity motor function will be assessed using the FMA-UE, which evaluates motor impairment and recovery of the affected upper extremity after stroke. The total FMA-UE motor score ranges from 0 to 66, with higher scores indicating better motor function.

    Time frame: Baseline, Week 4, and Week 8

Secondary outcomes

  1. Modified Ashworth Scale (MAS)

    Muscle tone of the affected upper extremity will be assessed using the MAS, focusing on the finger flexors. Scores range from 0 to 4, with higher scores indicating greater muscle tone/spasticity.

    Time frame: Baseline, Week 4, and Week 8

  2. Medical Research Council Scale (MRC) - Finger Flexion

    Muscle strength of the finger flexors of the affected hand will be assessed using the MRC Scale. Strength will be graded from 0 to 5, with higher scores indicating greater muscle strength. The finger flexion score will be recorded and analyzed separately from the finger extension score.

    Time frame: Baseline, Week 4, and Week 8

  3. Medical Research Council Scale (MRC) - Finger Extension

    Muscle strength of the finger extensors of the affected hand will be assessed using the MRC Scale. Strength will be graded from 0 to 5, with higher scores indicating greater muscle strength. The finger extension score will be recorded and analyzed separately from the finger flexion score.

    Time frame: Baseline, Week 4, and Week 8

  4. Hand Dynamometer (JAMAR)

    Grip strength of the affected hand will be measured using a JAMAR hand dynamometer. Three maximal grip attempts will be performed, and the mean value of the three measurements will be recorded in kilograms. Higher values indicate greater grip strength.

    Time frame: Baseline, Week 4, and Week 8

  5. Box and Block Test (BBT)

    Gross manual dexterity of the affected upper extremity will be assessed using the BBT. The outcome will be the number of blocks successfully transferred over the partition within 60 seconds. Higher scores indicate better gross manual dexterity.

    Time frame: Baseline, Week 4, and Week 8

  6. Modified Barthel Index (MBI)

    Functional independence in activities of daily living will be assessed using the MBΙ. The total score ranges from 0 to 100, with higher scores indicating greater functional independence.

    Time frame: Baseline, Week 4, and Week 8

  7. Visual Analogue Scale (VAS)

    Pain intensity in the affected upper extremity will be assessed using a 100-mm VAS, ranging from 0 to 100, where 0 indicates no pain and 100 indicates the maximum perceived pain. The anatomical location of pain will also be recorded when pain is present.

    Time frame: Baseline, Week 4, and Week 8

07

Study locations

1 site
  • ANAGENNISI Recovery and Rehabilitation Center of Thessaloniki
    Thermi, Central Macedonia 57001, Greece
    • Georgios Kalogirou, MSc · Contact · dot00005@uowm.gr · +30 6988787885
    • Georgios Kalogirou, Msc · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers because the study protocol does not include a predefined data-sharing plan. Participant data will be pseudonymized and used exclusively for the purposes of this doctoral research, in accordance with the approved protocol, institutional requirements, and applicable data protection regulations.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864090
Lead sponsor
University of Western Macedonia
Collaborators
ANAGENNISI Recovery and Rehabilitation Center of Thessaloniki
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Georgios Kalogirou, MSc
Contact
dot00005@uowm.gr
+30 6988787885
Ioannis Ventoulis, PhD
Contact
iventoulis@uowm.gr
Georgios Kalogirou, MSc
principal investigator · University of Western Macedonia
Ioannis Ventoulis, PhD
study chair · University of Western Macedonia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion